Drugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit growth in the next several quarters, primarily from the US market.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fNr3vL
via IFTTT
0 comments:
Post a Comment